Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Cholesterol: Significance and Regulation

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Valganciclovir for the treatment of cytomegalovirus infections in pediatric intestinal transplant recipients: A case series.

Pediatric transplantation·2021

See all related articles

Search research articles

Related Experiment Videos

Low Statin Use Post-liver Transplant Despite Increased Rates of Dyslipidemia.

Sarah Blocker^1,2, Molly Henry¹, Mary Leick^1,3

¹Department of Pharmaceutical and Nutrition Care, Nebraska Medicine, Omaha, NE, USA.

Journal of Pharmacy Practice

|July 13, 2026

Summary

Post-liver transplant, hyperlipidemia and statin qualification rates significantly increase. Despite this, statin therapy is underutilized in liver transplant recipients, highlighting a need for improved lipid management.

Keywords:

cardiovascular disease hyperlipidemia hypertriglyceridemia liver transplantation statin

Related Experiment Videos

Area of Science:

Cardiology
Hepatology
Pharmacology

Background:

Hyperlipidemia is a common complication following liver transplantation.
Current literature indicates low statin utilization post-liver transplant.
Assessment of statin qualification criteria in this patient population is limited.

Purpose of the Study:

To evaluate the incidence of hyperlipidemia post-liver transplant.
To determine the rate of statin therapy qualification and initiation in liver transplant recipients.
To characterize clinical practice behaviors related to lipid management in this cohort.

Main Methods:

Single center, retrospective cohort study.
Included adult patients who received an isolated liver transplant between January 1, 2015, and June 30, 2019.
Analyzed lipid panels within 15 months pre- and post-transplant, using 2012 AASLD and 2018 ACC/AHA guidance for outcomes.

Main Results:

Hyperlipidemia incidence increased from 21.5% pre-transplant to 49.4% post-transplant (P = 0.0003).
Statin qualification increased from 46.8% pre-transplant to 64.6% post-transplant (P = 0.025).
Only 43% of statin-qualifying patients initiated therapy; hypertriglyceridemia increased significantly post-transplant.

Conclusions:

Nearly two-thirds of liver transplant recipients qualify for statin therapy post-transplant.
Despite increased dyslipidemia and qualification rates, statin therapy remains underutilized.
Optimization of lipid management is a critical unmet need in post-liver transplant care.